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Introduction: UK guidelines recommend that all early active rheumatoid arthritis (RA) patients are offered
combination disease-modifying antirheumatic drugs (DMARDs) and short-term corticosteroids. Anti-citrullinated
protein antibody (ACPA)-positive and ACPA-negative RA may differ in their treatment responses. We used data from
a randomized controlled trial - the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trial - to examine
whether responses to intensive combination treatments in early RA differ by ACPA status.
Methods: The CARDERA trial randomized 467 early active RA patients to receive: (1) methotrexate, (2)
methotrexate/ciclosporin, (3) methotrexate/prednisolone or (4) methotrexate/ciclosporin/prednisolone in a
factorial-design. Patients were assessed every six months for two years. In this analysis we evaluated 431 patients with
available ACPA status. To minimize multiple testing we used a mixed-effects repeated measures ANOVA model to
test for an interaction between ACPA and treatment on mean changes from baseline for each outcome (Larsen,
disease activity scores on a 28-joint count (DAS28), Health Assessment Questionnaire (HAQ), EuroQol, SF-36 physical
component summary (PCS) and mental component summary (MCS) scores). When a significant interaction was
present, mean changes in outcomes were compared by treatment group at each time point using t-tests stratified
by ACPA status. Odds ratios (ORs) for the onset of new erosions with treatment were calculated stratified by ACPA.
Results: ACPA status influenced the need for combination treatments to reduce radiological progression. ACPA-positive
patients had significant reductions in Larsen score progression with all treatments. ACPA-positive patients receiving triple
therapy had the greatest benefits: two-year mean Larsen score increases comprised 3.66 (95% confidence interval (CI) 2.27
to 5.05) with triple therapy and 9.58 (95% CI 6.76 to 12.39) with monotherapy; OR for new erosions with triple therapy
versus monotherapy was 0.32 (95% CI 0.14 to 0.72; P = 0.003). ACPA-negative patients had minimal radiological progression
irrespective of treatment. Corticosteroid’s impact on improving DAS28/PCS scores was confined to ACPA-positive RA.
Conclusions: ACPA status influences the need for combination DMARDs and high-dose tapering corticosteroids in
early RA. In CARDERA, combination therapy was only required to prevent radiological progression in ACPA-positive
patients; corticosteroids only provided significant disease activity and physical health improvements in ACPA-positive
disease. This suggests ACPA is an important biomarker for guiding treatment decisions in early RA.
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Rheumatoid arthritis (RA) is a heterogeneous disease span-
ning several subsets. One crucial subdivision is defined by
the presence or absence of anti-citrullinated protein anti-
bodies (ACPA), termed ACPA-positive and ACPA-negative
RA, respectively [1]. ACPA-positive RA has a worse prog-
nosis with higher rates of erosive damage [2]. It also has
different risk factors than ACPA-negative RA with most
genetic associations [3,4] and environmental risks, such as
smoking [5] and alcohol abstinence [6], predominantly
linked to ACPA-positive disease. These disparities suggest
that RA ACPA subsets might respond differently to treat-
ment [7].
Current RA management focuses on early intensive
therapies, often using combinations of disease-modifying
antirheumatic drugs (DMARDs) and glucocorticoids with
rapid escalation to biologics in refractory cases. Guideline
recommendations for the treatment of early RA differ
across countries. UK guidelines from the National Insti-
tute for Health and Care Excellence (NICE) advocate that
all individuals with active RA are offered combination
DMARDs with short-term glucocorticoids [8]. American
College of Rheumatology (ACR) guidelines suggest reserv-
ing combination DMARDs for patients with markers of
severe disease, such as ACPA positivity [9]. The European
League Against Rheumatism (EULAR) guidelines also sug-
gest a stratified treatment approach, advocating biologics
in patients with poor prognostic markers like ACPA that
are failing to attain remission or low disease activity with
an initial treatment strategy of synthetic DMARDs [10].
There are, however, insufficient data on prognostic factors
in randomized controlled trials (RCTs) of combination
DMARDs and biologics to know which approach is best.
We used data from an RCT of combination DMARDs
and corticosteroids in early RA - the Combination Anti-
Rheumatic Drugs in Early RA (CARDERA) trial [11] - to
examine whether responses to intensive combination
treatments differ by ACPA status. Our primary aim was
to examine if combination DMARDs and corticosteroids
had different effects on radiological progression in ACPA-
positive and ACPA-negative RA. Our secondary aims were
to evaluate if any differential effects also extended to
disease activity, disability and quality of life (QoL).Methods
Ethical approval
The CARDERA trial was approved by the South Thames
Multicentre Research Ethics Committee (REC Reference:
MREC (1) 99/04). Further ethical approval was obtained
to process the archived serum for ACPA status from the
East of England - Essex Research Ethics Committee (REC
Reference: 11/EE/0544). Informed consent was obtained
from all patients recruited to the CARDERA trial.Subjects
The CARDERA trial recruited patients with early active
RA (of less than two years duration) from 42 UK cen-
ters; its details have previously been reported [11,12].
Patients were randomized to one of four treatment
arms: (1) monotherapy with methotrexate; (2) double
therapy with methotrexate and ciclosporin; (3) double
therapy with methotrexate and prednisolone; (4) triple
therapy with methotrexate, ciclosporin and prednisol-
one. A factorial-design was adopted to allow the simul-
taneous evaluation of prednisolone and ciclosporin in a
2 × 2 design. Treatment groups were well matched with
similar baseline characteristics [11]. Patients were
assessed every 6 months (for 24 months). Missing data
were imputed through last observations carried forward
(undertaken in 19% of patients at 24 months). We re-
stricted our current analysis to the 431 individuals
(from 467 recruited) who had their sera archived at
baseline and evaluable for ACPA.
Serological assessments
ACPA-status was evaluated using the commercial ELISA
assay, the Axis-Shield DIASTAT anti-CCP2 test (Axis-
Shield, Dundee, UK). All samples were processed in dupli-
cate with a cut-off of >5 units/ml taken as positive in
keeping with the manufacturer’s instructions. Rheumatoid
factor (RF) had been processed at recruiting center labora-
tories during the original trial.
Study treatments
Study treatments comprised: (1) methotrexate (starting
at 7.5 mg/week and increasing by 2.5 mg every two
weeks to a final dose of 15 mg/week); (2) “step-down”
prednisolone (based on the trial by Boers et al. [13],
comprising 60 mg/day in week 1, tapering to 7.5 mg/day
in weeks 7 to 28 and thereafter further reduced and
stopped by week 36) started with methotrexate; (3)
ciclosporin (based on the trial by Pasero et al. [14], com-
prising 1.5 mg/kg daily initially, increased gradually to a
target dose of 3 mg/kg daily) started three months after
methotrexate. Prednisolone and ciclosporin were given
as active tablets or placebos. Intra-articular glucocorti-
coids (40 mg methylprednisolone with lignocaine) were
given (on no more than six occasions) as required. Intra-
muscular glucocorticoids were allowed but only three
doses of 120 mg of depot methylprednisolone could be
given in a year.
Outcomes
The following disease outcomes were assessed: (1) radio-
logical damage - the onset of new erosions at 24 months
and modified Larsen scores; (2) disease activity - disease
activity scores on a 28-joint count (DAS28); (3) disability-
Health Assessment Questionnaire (HAQ); (4) QoL- SF-36
Figure 1 Number of individuals in each treatment group stratified by ACPA status. ACPA, anti-citrullinated protein antibody.
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scores and EuroQol.
Statistical analysis
Baseline differences between ACPA-positive and ACPA-
negative patients were evaluated using t-tests, Wilcoxon
signed-rank tests or chi-squared tests depending on data
type and distribution.
To establish whether treatment response differed by
ACPA status, we used a two-staged approach; this mini-
mized the potential for inflation of type I error associated
with multiple testing. The first stage used a mixed-effects
repeated measures ANOVA model to examine the effect
of ACPA, treatment (coded categorically as one of the four
randomized treatment arms) and time (assessment visit)
on mean changes in each RA outcome (Larsen, DAS28,
HAQ, EuroQol, PCS and MCS scores). The key compo-
nent of this model was an ACPA*treatment interactionTable 1 Baseline characteristics by ACPA status
Characteristic ACPA-positive (n = 310)
Female (number; %) 208 (67%)
RF positive (number; %) 244 (79%)
Age (years) 54.0 (46.0, 64.0)
Disease duration (months) 2.00 (0.00, 5.00)
Larsen score 7.50 (2.50, 21.25)*
DAS28 5.72 (4.91, 6.73)
HAQ 1.62 (1.00, 2.12)
EuroQol 0.60 (0.15, 0.68)
SF-36 PCS 28.68 (23.24, 35.95)
SF-36 MCS 38.64 (27.65, 53.71)
All data are median interquartile range (IQR) unless otherwise stated; 1 = t-test; 2 = c
in two ACPA-positive patients. ACPA, anti-citrullinated protein antibody; DAS28, dise
MCS, mental component summary; PCS, physical component summary; RF, rheumaterm, which established whether treatment responses dif-
fered by ACPA status.
The second stage was restricted to outcomes associated
with significant ACPA*treatment interactions and com-
pared mean changes in these outcomes by treatment
group at each time point using t-tests in ACPA-positive
and ACPA-negative patients. Where the ratio between
variances significantly differed from 1, Satterthwaite’s ap-
proximation was used to calculate the degrees of freedom
for the critical t-statistic. This second stage allowed us to
establish which treatments differed in their effects by
ACPA status and how these differences changed over
time. This analysis followed the original factorial grouping
by comparing the following treatment groups (Figure 1):
(a) active ciclosporin vs. placebo ciclosporin; (b) active
prednisolone vs. placebo prednisolone; (c) triple therapy
(methotrexate, cicosporin and prednisolone) vs. mono-
therapy (methotrexate).ACPA-negative (n = 121) Group difference
89 (74%) P = 0.1932
47 (39%) P <0.0012
55.0 (47.0, 62.0) P = 0.6611
1.00 (0.00, 4.00) P = 0.1063
4.50 (1.00, 9.50) P <0.0013
5.96 (4.92, 6.85) P = 0.3051
1.62 (1.12, 2.12) P = 0.5953
0.58 (0.08, 0.68) P = 0.5523
28.70 (22.90, 35.56) P = 0.7133
35.87 (25.37, 52.95) P = 0.2173
hi-squared test; 3 = Wilcoxon signed-rank test; *baseline Larsen scores missing
ase activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire;
toid factor.
Table 2 ANOVA results for the effect of ACPA, treatment and time on changes in RA outcomes
Larsen DAS28 HAQ EuroQol PCS MCS
Effects F P F P F P F P F P F P
ACPA 31.90 <0.001 4.02 0.045 7.25 0.007 9.72 0.002 4.07 0.044 2.29 0.131
Time 16.83 <0.001 1.26 0.288 1.37 0.251 0.70 0.550 0.80 0.493 0.65 0.584
Treatment 9.93 <0.001 1.71 0.163 17.76 <0.001 11.47 <0.001 5.67 0.001 1.92 0.124
ACPA*Treatment 7.05 <0.001 3.99 0.008 0.48 0.696 2.94 0.032 3.22 0.022 1.84 0.138
F = F-statistic; P = P-value; ACPA*Treatment = ACPA*Treatment interaction term. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a
28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RA, rheumatoid arthritis.
Figure 2 Treatment effect on mean changes in Larsen scores in ACPA-positive and ACPA-negative patients. Standard error bars are
shown for each time point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody.
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Table 3 Treatment effects on mean changes in Larsen and DAS28 scores in ACPA-positive and ACPA-negative RA
Time Ciclosporin Prednisolone Triple vs. monotherapy
Ciclosporin Placebo P Prednisolone Placebo P Triple Mono P
Larsen
ACPA+ 6 1.60 (0.37) 2.74 (0.44) 0.047 1.44 (0.22) 2.85 (0.53) 0.015 1.25 (0.28) 3.86 (0.80) 0.003
12 3.09 (0.47) 4.81 (0.61) 0.027 2.58 (0.35) 5.26 (0.67) 0.001 2.41 (0.52) 6.92 (1.10) <0.001
18 3.97 (0.53) 6.43 (0.78) 0.010 3.79 (0.48) 6.52 (0.80) 0.004 3.20 (0.66) 8.52 (1.39) 0.001
24 4.32 (0.58) 7.53 (0.84) 0.002 4.57 (0.57) 7.15 (0.84) 0.012 3.66 (0.70) 9.58 (1.41) <0.001
ACPA- 6 0.72 (0.30) 1.25 (0.36) 0.270 0.67 (0.29) 1.30 (0.37) 0.182 0.48 (0.35) 1.60 (0.55) 0.093
12 2.54 (1.11) 2.17 (0.59) 0.770 1.86 (0.58) 2.79 (1.04) 0.435 1.36 (0.47) 2.03 (0.66) 0.409
18 2.97 (1.30) 2.33 (0.60) 0.660 1.86 (0.56) 3.33 (1.21) 0.275 1.66 (0.64) 2.57 (0.79) 0.388
24 3.11 (1.32) 2.56 (0.61) 0.704 2.04 (0.60) 3.52 (1.22) 0.277 1.70 (0.69) 2.72 (0.77) 0.335
DAS28
ACPA+ 6 −1.61 (0.12) −1.49 (0.13) 0.488 −1.97 (0.12) −1.13 (0.11) <0.001 −1.98 (0.18) −0.99 (0.17) <0.001
12 −1.46 (0.12) −1.19 (0.14) 0.147 −1.36 (0.13) −1.29 (0.13) 0.716 −1.48 (0.18) −1.14 (0.19) 0.190
18 −1.49 (0.13) −1.36 (0.14) 0.498 −1.50 (0.14) −1.36 (0.13) 0.479 −1.64 (0.20) −1.37 (0.20) 0.356
24 −1.62 (0.13) −1.38 (0.15) 0.211 −1.62 (0.14) −1.38 (0.14) 0.203 −1.84 (0.19) −1.36 (0.22) 0.087
ACPA- 6 −1.02 (0.21) −1.42 (0.20) 0.173 −1.47 (0.24) −1.00 (0.17) 0.111 −1.43 (0.33) −1.32 (0.22) 0.792
12 −0.94 (0.21) −1.32 (0.21) 0.209 −1.01 (0.21) −1.25 (0.21) 0.421 −0.73 (0.33) −1.36 (0.33) 0.186
18 −1.33 (0.24) −1.52 (0.20) 0.552 −1.33 (0.23) −1.51 (0.22) 0.579 −1.27 (0.37) −1.62 (0.30) 0.462
24 −1.16 (0.22) −1.49 (0.20) 0.256 −1.32 (0.20) −1.34 (0.21) 0.960 −1.27 (0.32) −1.59 (0.30) 0.464
Data are mean changes (SE) unless otherwise stated; P = P-values from t-tests; Triple = triple DMARD therapy; Mono =monotherapy with methotrexate; time is in
months. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count.
Seegobin et al. Arthritis Research & Therapy 2014, 16:R13 Page 5 of 12
http://arthritis-research.com/content/16/1/R13In addition, we calculated odds ratios (ORs) for the
development of new erosions with each treatment using
binary logistic regression stratified by ACPA status.
P-values of <0.05 were considered significant. Analyses
were performed using SAS version 9.3 (SAS Institute,
Cary, NC, USA).Results
Patient characteristics
Of the 431 RA cases, 310 (72%) were ACPA-positive and
121 (28%) were ACPA-negative. Baseline characteristics
were similar between ACPA subsets with the exception of
Larsen scores and RF status (Table 1). ACPA-positive pa-
tients had more radiological damage at baseline; the differ-
ence in median Larsen scores between ACPA-subsets was
3.00 units (P <0.001). Significantly more ACPA-positive
patients were RF-positive (P <0.001). Both ACPA-positive
and ACPA-negative patients had median ages in the fifth
decade, were mainly female, had severely active RA (me-
dian DAS28 scores >5.1) of a short duration and moderate
disability (median HAQ scores 1.62). QoL was moderately
impaired (median EuroQol scores 0.58 to 0.60).Radiological progression
The first analytical step, using the ANOVAmodel (Table 2),
showed that treatment responses differed serologicallywith a significant ACPA*treatment interactive effect on
changes in Larsen scores observed (P <0.001).
The second analytical step, using the factorial approach,
showed significant reductions in Larsen score progression
in ACPA-positive patients receiving prednisolone, ciclos-
porin or triple therapy (Figure 2; Table 3). The magnitude
of effect was similar with prednisolone and ciclosporin.
Those receiving triple therapy had the largest reduction in
radiological progression; mean Larsen score increases over
24 months were 3.66 (95% confidence interval (CI) 2.27 to
5.05) with triple therapy and 9.58 (95% CI 6.76 to 12.39)
with monotherapy.
There were no significant treatment effects with any strat-
egy in ACPA-negative patients. These individuals showed
substantially less radiological progression (Figure 2; Table 3).
The mean Larsen score increase in ACPA-negative patients
treated with methotrexate monotherapy over 24 months
was 2.72 (95% CI 1.15 to 4.29); for those receiving triple
therapy the mean increase was 1.70 (95% CI 0.29 to 3.10).
Differences in radiological progression between ACPA-
subsets were also seen in the proportion of patients de-
veloping new erosions (24% of ACPA-positive patients;
7% of ACPA-negative patients). Reductions in erosion deve-
lopment in ACPA-positive patients were similar with cic-
losporin (OR 0.55; 95% CI 0.31 to 0.96; P = 0.032) and
prednisolone (OR 0.56; 95% CI 0.32 to 0.99; P= 0.045) when
compared with placebo. Triple therapy had the greatest
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monotherapy (OR 0.32; 95% CI 0.14 to 0.72; P = 0.003).
Treatment had no significant impact on preventing erosions
in ACPA-negative patients. The ORs for reduction in ero-
sion development in ACPA-negative patients comprised
0.86 (95% CI 0.16 to 4.23; P = 1.00) and 0.89 (95% CI 0.17
to 4.38; P = 1.00) with ciclosporin and prednisolone, respect-
ively, compared to placebo and 0.79 (95% CI 0.06 to 7.53;
P = 1.00) for triple therapy compared with monotherapy.
Disease activity
The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in DAS28 scoresFigure 3 Treatment effect on mean changes in DAS28 scores in ACPA
shown for each time point; *denotes significance at P <0.05; **denotes sig
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody; DAS28, disease a(P = 0.008). Subsequent factorial analysis by treatment
showed that prednisolone (P <0.001) and triple therapy
(P <0.001) significantly reduced DAS28 scores at six
months in ACPA-positive patients (Figure 3; Table 3).
No treatment effects were seen at subsequent time
points. There were no significant treatment effects in
ACPA-negative patients.Disability
The ANOVA model (Table 2) showed that although ACPA
status (P = 0.007) and treatment (P <0.001) influenced
changes in HAQ scores no ACPA*treatment interaction-positive and ACPA-negative patients. Standard error bars are
nificance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
ctivity scores on a 28 joint count.
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The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in EuroQol scores
(P = 0.032). Subsequent factorial analysis (Figure 4; Table 4)
showed significant improvements in EuroQol scores at 6
months in ACPA-positive patients receiving prednisolone
(P = 0.001) or triple therapy (P = 0.029); a significant effect
was also seen at 12 months with ciclosporin (P = 0.044). AFigure 4 Treatment effect on mean changes in EuroQol scores in ACP
shown for each time-point; *denotes significance at P <0.05; **denotes sig
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody.significant effect of prednisolone on EuroQol scores was
seen at all time-points in ACPA-negative patients.
SF-36 PCS
The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in PCS scores (P =
0.022). Factorial analysis (Figure 5; Table 4) showed that in
ACPA-positive patients, prednisolone and triple therapy
significantly improved PCS scores at 6 and 12 months;
ciclosporin also improved PCS scores at 6 months (P =
0.031). In ACPA-negative patients no significant treatment
effect on PCS scores was observed.A-positive and ACPA-negative patients. Standard error bars are
nificance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
Table 4 Treatment effects on mean changes in EuroQol and PCS scores in ACPA-positive and ACPA-negative RA
Ciclosporin Prednisolone Triple vs. monotherapy
Time Ciclosporin Placebo P Prednisolone Placebo P Triple Mono P
EuroQol
ACPA+ 6 0.16 (0.02) 0.16 (0.02) 0.978 0.21 (0.02) 0.11 (0.02) 0.001 0.21 (0.03) 0.11 (0.04) 0.029
12 0.16 (0.02) 0.09 (0.03) 0.044 0.14 (0.02) 0.12 (0.02) 0.481 0.19 (0.03) 0.10 (0.04) 0.063
18 0.15 (0.02) 0.11 (0.03) 0.215 0.14 (0.03) 0.13 (0.02) 0.651 0.18 (0.04) 0.12 (0.04) 0.267
24 0.17 (0.02) 0.12 (0.03) 0.176 0.16 (0.03) 0.13 (0.02) 0.403 0.20 (0.04) 0.12 (0.04) 0.152
ACPA- 6 0.08 (0.04) 0.09 (0.04) 0.876 0.16 (0.04) 0.02 (0.04) 0.011 0.19 (0.06) 0.05 (0.05) 0.074
12 0.08 (0.04) 0.06 (0.04) 0.756 0.14 (0.04) 0.01 (0.04) 0.033 0.14 (0.05) 0.00 (0.05) 0.057
18 0.10 (0.04) 0.09 (0.04) 0.776 0.16 (0.04) 0.03 (0.04) 0.036 0.19 (0.06) 0.05 (0.05) 0.058
24 0.10 (0.04) 0.09 (0.04) 0.908 0.16 (0.04) 0.04 (0.04) 0.035 0.21 (0.05) 0.08 (0.05) 0.057
PCS
ACPA+ 6 7.96 (0.89) 5.15 (0.95) 0.031 9.15 (0.96) 4.01 (0.83) <0.001 10.42 (1.30) 2.29 (1.16) <0.001
12 5.27 (0.84) 4.17 (0.94) 0.380 6.04 (0.93) 3.42 (0.84) 0.037 7.05 (1.23) 3.28 (1.27) 0.035
18 6.11 (0.89) 3.87 (1.02) 0.097 5.51 (1.01) 4.53 (0.89) 0.472 7.77 (1.39) 4.58 (1.44) 0.114
24 5.77 (0.96) 4.91 (1.03) 0.544 6.36 (1.03) 4.34 (0.95) 0.150 8.33 (1.46) 5.53 (1.49) 0.180
ACPA- 6 2.64 (1.41) 4.04 (1.21) 0.449 4.14 (1.31) 2.68 (1.29) 0.428 4.86 (2.11) 4.54 (1.78) 0.908
12 3.27 (1.35) 4.93 (1.15) 0.349 3.70 (1.25) 4.52 (1.25) 0.646 3.25 (2.07) 5.61 (1.76) 0.386
18 3.86 (1.38) 5.06 (1.24) 0.516 4.41 (1.40) 4.55 (1.23) 0.937 4.72 (2.11) 5.88 (1.67) 0.664
24 4.65 (1.69) 5.17 (1.07) 0.793 5.51 (1.58) 4.40 (1.21) 0.575 7.44 (2.70) 6.48 (1.36) 0.753
Data are mean changes (SE) unless otherwise stated; P = P-values from t-tests; Triple = triple DMARD therapy; Mono =monotherapy with methotrexate; time is in
months. ACPA, anti-citrullinated protein antibody; PCS, physical component summary.
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The ANOVA model (Table 2) showed no significant as-
sociations between ACPA, time or treatment and MCS
scores; no ACPA*treatment interaction was observed (P =
0.138). Factorial analysis was therefore not undertaken.
Discussion
Our main finding is that combination DMARDs and
high-dose tapering corticosteroids are only required to
prevent radiological progression in patients with early
active RA in whom ACPA is present. In ACPA-positive
patients, methotrexate monotherapy resulted in consid-
erable worsening of radiological damage; the average
annual Larsen score increase was 4.8 units and 38%
developed new erosions. This was significantly reduced
with combination treatment; in ACPA-positive patients
receiving triple therapy the average annual Larsen score
increase was 1.8 units and 16% developed new erosions.
In contrast, ACPA-negative patients had minimal radio-
logical progression irrespective of the treatment strategy
used; the average annual increases in Larsen scores were
below the minimal clinically important difference (MCID)
of 2.3 units [15] with all treatments and only 7% developed
new erosions.
Our other finding was that the beneficial effect of high-
dose corticosteroids on reducing disease activity and im-
proving physical health was also confined to ACPA-positiveRA. Only ACPA-positive patients had significant six-month
improvements in DAS28 and PCS scores with double and
triple therapy regimens incorporating prednisolone. Our
findings are consistent with the IMPROVED study, which
also found that high-dose corticosteroids had a significantly
larger effect on improving disease activity and remission
rates in ACPA-positive, as compared to ACPA-negative,
inflammatory arthritis patients [16]. The mechanism un-
derlying this differential steroid response is uncertain. The
fact these improvements were not maintained over time in
CARDERA is expected and consistent with the original
COBRA study [13]. Our results support the use of high-
dose tapering corticosteroids as a bridging therapy in early
RA but suggest this treatment strategy would be best
reserved for ACPA-positive patients.
The impact of ACPA status on EuroQol responses to
combination DMARDs and corticosteroids was less clear,
with similar EuroQol improvements observed in ACPA-
positive and ACPA-negative patients receiving active pred-
nisolone and triple therapy. Interestingly, ACPA-negative
patients receiving placebo prednisolone or methotrexate
monotherapy had substantially smaller EuroQol improve-
ments (maximal increase of 0.04 and 0.08 units, respect-
ively) when compared to ACPA-positive patients (maximal
increase of 0.13 and 0.12 units, respectively). This suggests
that methotrexate monotherapy could be more effective at
improving QoL in ACPA-positive disease.
Figure 5 Treatment effect on mean changes in PCS scores in ACPA-positive and ACPA-negative patients. Standard error bars are shown
for each time point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk denotes
P ≥0.05. ACPA, anti-citrullinated protein antibody; PCS, physical component summary.
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tus on responses to combination DMARDs and corticoste-
roids is limited to secondary analyses or extension studies
of the BeST [17,18] and FIN-RACo [19] trials. Data from
the BeST study support our finding that DMARD mo-
notherapy is inadequate at preventing radiological prog-
ression in ACPA-positive RA; the presence of ACPA
associated with radiological progression in individuals re-
ceiving monotherapy (OR for radiological progression:
12.6; 95% CI 3.0 to 51.9) but not combination therapy
with DMARDs and corticosteroids (OR 1.7; 95% CI 0.5
to 5.4) [17]. This study also reported minimal radiologicalprogression in ACPA-negative patients in all treatment
groups. Although the FIN-RACo trial found that combin-
ation therapy reduced radiological progression in ACPA-
negative, but not ACPA-positive patients, the study had a
small sample size, allowed corticosteroids in both treat-
ment arms and had no treatment restrictions for the last
three years of follow-up [19]. The impact of ACPA-status
on biologic responses has been studied in greater detail,
particularly in national registries. Anti-tumor necrosis
factor (anti-TNF) therapies appear more effective in ACPA-
negative disease [20,21]. Conversely, T-cell and B-cell in-
hibition with abatacept and rituximab, respectively, appear
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together these findings suggest that treatment responses
differ between ACPA-positive and ACPA-negative RA.
This highlights a requirement for future RCTs of RA treat-
ments to stratify their analyses by ACPA status.
Our results show that ACPA is an important prognos-
tic biomarker in early RA, with its presence signaling a
requirement for intensive combination treatment. The
heterogeneous nature of RA alongside the increasing
breadth of available therapies means that identifying
predictors of treatment responses is a key research goal.
Studies have identified several clinical parameters asso-
ciated with good anti-TNF outcomes; these include not
smoking, male gender and a younger age [20,24]. Gen-
etic markers also offer promise with a recent large
genome-wide association study reporting the first de-
finitive genetic association (in the CD84 gene) with
anti-TNF response [25]. Other smaller studies suggest
that stimulated whole blood cell pro-inflammatory cyto-
kine levels [26] and serum proteins [27] may be useful
in predicting anti-TNF efficacy. These findings are promis-
ing but lack clinical utility, since most markers require
validation in larger cohorts or associate with only small
differences in treatment response. Further work is re-
quired to identify predictors of treatment responses
in RA.
Our study has a number of strengths. These include its
large sample size, the involvement of multiple centers, the
measurement of a wide range of outcomes and the use of
two-year follow-up data. It also has several limitations. It
was a secondary analysis of a published RCT and, there-
fore, neither its primary hypothesis nor its statistical ana-
lysis plan was pre-specified. ACPA status was unknown in
8% of patients, who were excluded from our analysis. One
DMARD, ciclosporin, is not widely used in current prac-
tice. Fewer ACPA-negative patients were studied; however,
the power to detect a MCID in Larsen scores between
combination therapy and monotherapy treatment arms in
ACPA-negative patients was higher (86%) than in ACPA-
positive patients (55%). Finally, the maximal dose of me-
thotrexate was 15 mg/week; higher doses are often used in
contemporary clinical care [28].
Different guidelines, constructed using the same evi-
dence base, have drawn alternative conclusions regard-
ing the optimal treatment of early active RA. NICE
guidelines recommend offering all patients combination
DMARDs and short-term corticosteroids [8]. ACR and
EULAR guidelines recommend adopting an individual-
ized approach to treatment intensity based on prognos-
tic factors, such as ACPA [9,10]. Our findings favor this
latter approach. They show strong evidence that ACPA-
positive patients benefit from intensive combination ther-
apy but no evidence that combination treatments improve
disease outcomes beyond methotrexate monotherapyin ACPA-negative patients. We recommend that future
trials in early RA should consider ACPA status when
evaluating treatment outcomes. When NICE and other
clinical guidelines are updated, the heterogeneity of RA
requires consideration, particularly the impact of ACPA-
status on treatment requirements and responses.
Conclusions
We have demonstrated that the requirement for, and re-
sponse to, combination DMARDs and high-dose tapering
corticosteroids differs between patients with ACPA-positive
and ACPA-negative early RA. In our study, intensive com-
bination therapy was only needed to prevent radiological
progression in ACPA-positive patients. Additionally, cor-
ticosteroids only provided significant improvements in
disease activity and physical health outcomes in ACPA-
positive RA. These findings suggest that ACPA is an
important biomarker for guiding treatment decisions in
early RA. They support ACR and EULAR RA manage-
ment guidelines, which recommend an individualized
approach to treatment intensity based on prognostic
factors such as ACPA.
Abbreviations
ACPA: Anti-citrullinated protein antibodies; ACR: American College of
Rheumatology; anti-TNF: Anti-tumor necrosis factor; CARDERA: Combination
Anti-Rheumatic Drugs in Early RA; CI: Confidence interval; DAS28: Disease
activity score on a 28-joint count; DMARD: Disease-modifying anti-rheumatic
drug; EULAR: The European League Against Rheumatism; HAQ: Health
assessment questionnaire; MCID: Minimal clinically important difference;
MCS: Mental component summary; NICE: National Institute for Health and
Care Excellence; OR: Odds ratio; PCS: Physical component summary;
QoL: Quality of life; RA: Rheumatoid arthritis; RCT: Randomised controlled
trial; RF: Rheumatoid factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ICS and DLS conceived and designed the study. ICS, MHYM and CD carried out
the ACPA ELISA assays. SDS, ICS and CML performed the statistical analysis. SDS,
ICS, CML and APC interpreted the data. ICS, SDS, CML, APC and DLS drafted the
manuscript. All authors revised the manuscript critically for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by Arthritis Research UK (Grant Reference Number
19739 to ICS). It represents research arising from an Arthritis Research UK
funded Clinical Research Fellowship (ICS). It also presents independent
research funded by the National Institute for Health Research (NIHR) under
its Research for Patient Benefit (RfPB) Programme (Grant Reference Number
PB-PG-1208-18256). MHYM is a recipient of an NIHR Doctoral Research
Fellowship (Grant Reference Number DRF-2009-02-86). The views expressed
are those of the authors and not necessarily those of the NHS, the NIHR or
the Department of Health. We also acknowledge support from the NIHR
Biomedical Research Centre at Guy’s and St. Thomas’ NHS Foundation Trust
in partnership with King’s College London. The funders had no role in the
study design, data collection and analysis, data interpretation, the writing of
the manuscript or the decision to submit the manuscript for publication.
Author details
1Department of Medical and Molecular Genetics, King’s College London,
Guy’s Hospital, Great Maze Pond, 8th Floor Tower Wing, London SE1 9RT, UK.
2Academic Department of Rheumatology, Centre for Molecular and Cellular
Seegobin et al. Arthritis Research & Therapy 2014, 16:R13 Page 11 of 12
http://arthritis-research.com/content/16/1/R13Biology of Inflammation, 1st Floor, New Hunt’s House, Guy’s Campus, King’s
College London, Great Maze Pond, London SE1 1UL, UK. 3Department of
Rheumatology, 3rd Floor, Weston Education Centre, King’s College Hospital,
Cutcombe Road, London SE5 9RJ, UK.
Received: 15 September 2013 Accepted: 27 December 2013
Published: 16 January 2014
References
1. Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet 2010,
376:1094–1108.
2. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW:
Antibodies to citrullinated proteins and differences in clinical progression
of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949–R958.
3. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E,
Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C,
Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S,
Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D, et al:
High-density genetic mapping identifies new susceptibility loci for
rheumatoid arthritis. Nat Genet 2012, 44:1336–1340.
4. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M,
Alfredsson L, Klareskog L: Epidemiological Investigation of Rheumatoid
Arthritis study group: a genome-wide association study suggests
contrasting associations in ACPA-positive versus ACPA-negative
rheumatoid arthritis. Ann Rheum Dis 2011, 70:259–265.
5. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J,
Ronnelid J, Harris HE, Ulfgren A-K, Rantapaa-Dahlqvist S, Eklund A, Padyukov L,
Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking
may trigger HLA-DR (shared epitope)-restricted immune reactions to
autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38–46.
6. Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP: The protective effect
of alcohol on developing rheumatoid arthritis: a systematic review and
meta-analysis. Rheumatology 2013, 52:856–867.
7. Daha NA, Toes RE: Rheumatoid arthritis: are ACPA-positive and ACPA-
negative RA the same disease? Nat Rev Rheumatol 2011, 7:202–203.
8. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M: Guideline
Development Group: management of rheumatoid arthritis: summary of
NICE guidance. BMJ 2009, 338:b702.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW,
O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE,
Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL,
Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER,
Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: 2012 update of the 2008
American College of Rheumatology recommendations for the use of
disease-modifying antirheumatic drugs and biologic agents in the
treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625–639.
10. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C,
Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L,
Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J,
Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P,
Scholte M, Scott DL, Sokka T, Valesini G, et al: EULAR recommendations for
the management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964–975.
11. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL,
CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis)
Trial Group: Factorial randomised controlled trial of glucocorticoids and
combination disease modifying drugs in early rheumatoid arthritis.
Ann Rheum Dis 2008, 67:656–663.
12. Ma MH, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PD, Williams R, Walsh DA,
Young A, Scott DL: Remission in early rheumatoid arthritis: predicting
treatment response. J Rheumatol 2012, 39:470–475.
13. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R,
van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den
Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S:
Randomised comparison of combined step-down prednisolone,
methotrexate and sulphasalazine with sulphasalazine alone in early
rheumatoid arthritis. Lancet 1997, 350:309–318.
14. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M,
Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della
Casa-Alberighi O: Slow progression of joint damage in early rheumatoid
arthritis treated with cyclosporin A. Arthritis Rheum 1996, 39:1006–1015.15. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H,
Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, van der Linden S:
Determination of the minimal clinically important difference in
rheumatoid arthritis joint damage of the Sharp/van der Heijde and
Larsen/Scott scoring methods by clinical experts and comparison with
the smallest detectable difference. Arthritis Rheum 2002, 46:913–920.
16. Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendael JH,
Peeters AJ, Westedt M-L, Collée G, de Sonnaville PBJ, Grillet BA, Huizinga TW,
Allaart CF: Remission induction therapy with methotrexate and
prednisone in patients with early rheumatoid and undifferentiated
arthritis (the IMPROVED study). Ann Rheum Dis 2012, 71:1472–1477.
17. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM,
Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC,
Dijkmans BA, Huizinga TW, Allaart CF: Progression of joint damage in early
rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and
anti-citrullinated protein antibodies in relation to different treatment
strategies. Arthritis Rheum 2008, 58:1293–1298.
18. van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens
PJ, Huizinga TW, Dijkmans BA, Allaart CF: The association of treatment
response and joint damage with ACPA-status in recent-onset RA: a
subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis
2012, 71:245–248.
19. Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Mottonen T,
Leirisalo-Repo M, Ilonen J, Jarvenpaa S, Luukkainen R, Hannonen P:
Anti-citrullinated peptide antibodies and the progression of radiographic
joint erosions in patients with early rheumatoid arthritis treated with
FIN-RACo combination and single disease-modifying antirheumatic drug
strategies. Clin Exp Rheumatol 2011, 29:500–505.
20. Canhao H, Rodrigues AM, Mourao AF, Martins F, Santos MJ, Canas-Silva J,
Polido-Pereira J, Pereira Silva JA, Costa JA, Araujo D, Silva C, Santos H, Duarte C,
da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE,
Solomon DH: Comparative effectiveness and predictors of response to
tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
Rheumatology 2012, 51:2020–2026.
21. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W,
Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A,
BRAGGSS: Association of rheumatoid factor and anti-cyclic citrullinated
peptide positivity, but not carriage of shared epitope or PTPN22
susceptibility variants, with anti-tumour necrosis factor response in
rheumatoid arthritis. Ann Rheum Dis 2009, 68:69–74. Erratum in:
Ann Rheum Dis 2011, 70:1519.
22. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T,
Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loet X,
Marcelli C, Bardin T, Pane I, Baron G, Mariette X: Positivity for anti-cyclic
citrullinated peptide is associated with a better response to abatacept:
data from the ‘Orencia and Rheumatoid Arthritis’registry. Ann Rheum Dis
2012, 71:1815–1819.
23. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ:
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody
serotype on rituximab clinical response: a meta-analysis.
Ann Rheum Dis 2013, 72:329–336.
24. Kleinert S, Tony H-P, Krause A, Feuchtenberger M, Wassenberg S, Richter C,
Rother E, Spieler W, Gnann H, Wittig BM: Impact of patient and disease
characteristics on therapeutic success during adalimumab treatment of
patients with rheumatoid arthritis: data from a German noninterventional
observational study. Rheumatol Int 2012, 32:2759–2767.
25. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU,
Canhao H, Ikari K, Terao C, Okada Y, Wedren S, Askling J, Yamanaka H,
Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N,
Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M,
Doorenspleet ME, Tak P-P, Crusius JB, et al: Genome-wide association study
and gene expression analysis identifies CD84 as a predictor of response
to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013,
9:e1003394.
26. Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, Kaneko Y,
Maeshima A, Hiromura K, Nojima Y: Interleukin-1 measurement in
stimulated whole blood cultures is useful to predict response to
anti-TNF therapies in rheumatoid arthritis. Rheumatology 2012,
51:1639–1643.
27. Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonzalez I,
Gomez-Reino JJ, Gonzalez A: Discovery of serum proteomic biomarkers
Seegobin et al. Arthritis Research & Therapy 2014, 16:R13 Page 12 of 12
http://arthritis-research.com/content/16/1/R13for prediction of response to infliximab (a monoclonal anti-TNF
antibody) treatment in rheumatoid arthritis: an exploratory analysis.
J Proteomics 2012, 77:372–382.
28. Visser K, van der Heijde D: Optimal dosage and route of administration of
methotrexate in rheumatoid arthritis: a systematic review of the
literature. Ann Rheum Dis 2009, 68:1094–1099.
doi:10.1186/ar4439
Cite this article as: Seegobin et al.: ACPA-positive and ACPA-negative
rheumatoid arthritis differ in their requirements for combination
DMARDs and corticosteroids: secondary analysis of a randomized
controlled trial. Arthritis Research & Therapy 2014 16:R13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
